3 / 4
June 27-28, 2019 | Amsterdam, Netherlands
12
th
World congress on
Joint Event
4
th
Pharmaceutical Chemistry Conference Future Pharma
Page 26
Research & Reviews: Journal ofPharmaceutical Analysis | ISSN : 2320-0812
Volume 08
Euro Pharma Chemistry & Future Pharma 2019
Increasing performance and throughput of ELISA
procedures through implementation of ready-to-use
plates and optimisation of the binding kinetics of the
capture and detection antibodies
A
pplications of the enzyme-linked immunosorbent assay (ELISA)
are very common in a variety of biological disciplines. In the
biopharmaceutical industry ELISAs are utilised for measuring drug
substance and residual proteins for quality control and process development.
However, they are labour intensive and lengthy procedures. This limits their
throughput and hence determines a need to modify ELISA procedures to
enhance their efficiency. We have previously described modifications of
the transferrin ELISA procedure incorporating simultaneous addition
of antigen and detection antibody and elimination of some washing
steps, which significantly improved the performance of the method. In
parallel the use of automated high throughput ELISA platforms and their
advantages and limitations were discussed. The transferrin ELISA was used
as a model to assess the effectiveness of the proposed modifications and
could be extended to embrace other assays. Here we present our studies
on additional optimisation approaches for ELISA techniques comprising
preparation of ready-to-use plates and improved binding kinetics of capture
and detection antibodies. These optimisations allow for further increase
in sample throughput and maximisation of the performance of ELISA
procedures. Following the implementation of the proposed modifications
the overall duration of the assay was reduced from 4.5 hours to less than 1.5
hours without compromising the accuracy and precision parameters. The
modified ELISA procedures could be easily adopted in QC, R&D and other
analytical laboratories to replace the conventional methods. This would
significantly improve the performance capabilities and economical efficency
of the assays without a need to adopt highly expensive technologies.
Biography
Vladimir Gurevich has completed his PhD from the Moscow Academy of Veterinary Science
and then worked in various areas of Veterinary and Medical Research. He was awarded several
research grants. He is a Senior Scientist of the Bioanalytical Sciences in the Department of
the Plasma Product Development Division of the CSL Behring (Australia) Pty Ltd., a leading
biopharmaceutical company. His research has been published in many veterinary and medical
peer-reviewed journals and presented at national and international conferences.
vladimir.gurevich@cslbehring.com.auVladimir Gurevich
CSL Behring, Australia
Vladimir Gurevich et al., Pharmaceutical Analysis 2019, Volume 08
Co-Authors
K McCann
and
J Bertolini
CSL Behring, Australia